Literature DB >> 6158237

Is the use of Ro 10-9359 (Tigason) in children justified?

H J van der Rhee, H H van Gelderen, M K Polano.   

Abstract

In 5 children ranging in age from 8 to 12 years, treatment with Ro 10-9359 for either psoriasis or erythrokeratodermia variabilis for periods of between 11 and 17 months did not cause marked growth retardation and gave excellent therapeutic results.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6158237

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   4.437


  2 in total

Review 1.  Etretinate therapy in children with severe keratinization defects.

Authors:  H Traupe; R Happle
Journal:  Eur J Pediatr       Date:  1985-01       Impact factor: 3.183

2.  Psoriasis in children: an insight.

Authors:  Sandipan Dhar; Raghubir Banerjee; Nilesh Agrawal; Sharmila Chatterjee; Rajib Malakar
Journal:  Indian J Dermatol       Date:  2011-05       Impact factor: 1.494

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.